Tocilizumab for Renal Graft Inflammation

Inclusion Criteria: * All kidney transplant recipients with SCI on 6-month surveillance biopsy. * Maintenance immunosuppression regimens containing tacrolimus and MMF with or without prednisone. * Ability to provide written informed consent for the study. * Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment. Exclusion Criteria: General: • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization. Excluded Previous or Concomitant Therapy: * Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of screening. * Previous treatment with any cell-depleting therapies, including investigational agents or approved therapies, some examples are CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19 and anti-CD20, except Thymoglobulin. * Treatment with intravenous gamma globulin, plasmapheresis or Prosorba column within 6 months of baseline. * Immunization with a live/attenuated vaccine within 4 weeks prior to baseline. * Previous treatment with TCZ (an exception to this criterion may be granted for single dose exposure upon application to the sponsor on a case-by-case basis). * Any previous treatment with alkylating agents such as chlorambucil, or with total lymphoid irradiation. Exclusions for General Safety: * Presence of acut…